Projections for the near future indicate that the glucagon-like peptide GLP-1 agonists weight loss drugs market size will continue to surge, reaching $28.91 billion in 2029 at a CAGR of 16.6%.

The global glucagon-like peptide-1 (GLP-1) agonists market was valued at USD 19.70 billion in 2024, driven by the rising prevalence of type 2 diabetes and obesity across the globe.

Objective: To evaluate the effect of combination therapy with pioglitazone and glucagon-like peptide (GLP)-1 in patients with type 2 diabetes. Conclusions: GLP-1 and pioglitazone show an additive ...

Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine ...

Learn how the benefits of GLP-1s may be outweighed by the risks.

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

As weight loss jabs like Ozempic and Wegovy become ever more popular, doctors are growing increasingly concerned about their ...

While we have commonly heard of common side effects of weight loss jabs such as nausea and constipation, there is a new concern that experts are highlighting and users are discussing across support ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new study into side effects of GLP-1 medicines (glucagon-like peptide-1 receptor agonists) ...